These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28633309)

  • 1. TMPRSS2:ERG Gene Fusions in Prostate Cancer of West African Men and a Meta-Analysis of Racial Differences.
    Zhou CK; Young D; Yeboah ED; Coburn SB; Tettey Y; Biritwum RB; Adjei AA; Tay E; Niwa S; Truelove A; Welsh J; Mensah JE; Hoover RN; Sesterhenn IA; Hsing AW; Srivastava S; Cook MB
    Am J Epidemiol; 2017 Dec; 186(12):1352-1361. PubMed ID: 28633309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TMPRSS2-ERG fusions linked to prostate cancer racial health disparities: A focus on Africa.
    Blackburn J; Vecchiarelli S; Heyer EE; Patrick SM; Lyons RJ; Jaratlerdsiri W; van Zyl S; Bornman MSR; Mercer TR; Hayes VM
    Prostate; 2019 Jul; 79(10):1191-1196. PubMed ID: 31090091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
    Jiang H; Mao X; Huang X; Zhao J; Wang L; Xu J; Zhang H; Lu Y; Yu Y
    Tumour Biol; 2016 Sep; 37(9):12397-12402. PubMed ID: 27320318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
    Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
    Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
    Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retention of Interstitial Genes between
    Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
    Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
    [No Abstract]   [Full Text] [Related]  

  • 8. TMPRSS2:ETS fusions and clinicopathologic characteristics of prostate cancer patients from Eastern China.
    Dong J; Xiao L; Sheng L; Xu J; Sun ZQ
    Asian Pac J Cancer Prev; 2014; 15(7):3099-103. PubMed ID: 24815454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM; Mehra R; Regan MM; Perner S; Genega EM; Bueti G; Shah RB; Gaston S; Tomlins SA; Wei JT; Kearney MC; Johnson LA; Tang JM; Chinnaiyan AM; Rubin MA; Sanda MG
    Clin Cancer Res; 2009 Jul; 15(14):4706-11. PubMed ID: 19584163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.
    Krstanoski Z; Vokac NK; Zagorac A; Pospihalj B; Munda M; Dzeroski S; Golouh R
    BMC Urol; 2016 Jul; 16(1):35. PubMed ID: 27377958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues.
    Tu JJ; Rohan S; Kao J; Kitabayashi N; Mathew S; Chen YT
    Mod Pathol; 2007 Sep; 20(9):921-8. PubMed ID: 17632455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The progress of TMPRSS2-ETS gene fusions and their mechanism in prostate cancer].
    Guo XQ; Gui YT; Cai ZM
    Yi Chuan; 2011 Feb; 33(2):117-22. PubMed ID: 21377967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical application of
    Kong DP; Chen R; Zhang CL; Zhang W; Xiao GA; Wang FB; Ta N; Gao X; Sun YH
    Asian J Androl; 2020; 22(2):200-207. PubMed ID: 31210145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
    Merdan S; Tomlins SA; Barnett CL; Morgan TM; Montie JE; Wei JT; Denton BT
    Cancer; 2015 Nov; 121(22):4071-9. PubMed ID: 26280815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis.
    Pettersson A; Graff RE; Bauer SR; Pitt MJ; Lis RT; Stack EC; Martin NE; Kunz L; Penney KL; Ligon AH; Suppan C; Flavin R; Sesso HD; Rider JR; Sweeney C; Stampfer MJ; Fiorentino M; Kantoff PW; Sanda MG; Giovannucci EL; Ding EL; Loda M; Mucci LA
    Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1497-509. PubMed ID: 22736790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers.
    Fleischmann A; Saramäki OR; Zlobec I; Rotzer D; Genitsch V; Seiler R; Visakorpi T; Thalmann GN
    Prostate; 2014 Dec; 74(16):1647-54. PubMed ID: 25252136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG.
    Pernar CH; Ebot EM; Pettersson A; Graff RE; Giunchi F; Ahearn TU; Gonzalez-Feliciano AG; Markt SC; Wilson KM; Stopsack KH; Gazeeva E; Lis RT; Parmigiani G; Rimm EB; Finn SP; Giovannucci EL; Fiorentino M; Mucci LA
    Eur Urol; 2019 Jul; 76(1):33-40. PubMed ID: 30301696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
    Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
    J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
    Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.